Skip to Content

Utac (methenamine / sodium acid phosphate) Disease Interactions

There are 5 disease interactions with Utac (methenamine / sodium acid phosphate):

Major

Methenamine (Includes Utac) ↔ crystalluria

Severe Potential Hazard, High plausibility. Applies to: Renal Dysfunction, Dehydration

The use of methenamine salts (i.e. methenamine hippurate or mandelate), but not the base, is contraindicated in patients with severe renal impairment or dehydration. Methenamine is excreted by the kidney and concentrated in the urine. In patients with low urinary output, the salts can precipitate and cause crystalluria.

References

  1. Klinge E, Mannisto P, Mantyla R, Lamminsivu U, Ottoila P "Pharmacokinetics of methenamine in healthy volunteers." J Antimicrob Chemother 9 (1982): 209-16
  2. Australian Drug Evaluation Committee "Adverse effects of drugs commonly used in the treatment of urinary tract infection." Med J Aust 1 (1972): 435-8
  3. "Product Information. Hiprex (methenamine)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  4. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
  5. "Product Information. Mandelamine (methenamine)." Parke-Davis, Morris Plains, NJ.
  6. Gleckman R, Alvarez S, Joubert D, Matthews S "Drug therapy reviews: methenamine mandelate and methenamine hippurate." Am J Hosp Pharm 36 (1979): 1509-12
View all 6 references
Major

Methenamine (Includes Utac) ↔ gout

Severe Potential Hazard, Moderate plausibility. Applies to: Gout

Methenamine mandelate (salts), should be avoided in patients with gout as it may precipitate urate crystals in their urine. A similar situation may arise in patients with a predisposition to the formation of uric acid stones.

Major

Methenamine (Includes Utac) ↔ liver disease

Severe Potential Hazard, High plausibility. Applies to: Liver Disease

The use of methenamine and its salts (i.e. methenamine hippurate or mandelate) is contraindicated in patients with severe hepatic impairment. Methenamine is hydrolyzed to ammonia and formaldehyde in the urine under acidic conditions. Patients with liver disease may already have elevated ammonia levels, which can cause or exacerbate hepatic encephalopathy. Methenamine hippurate has also been associated with isolated cases of transient elevations in serum transaminases. The manufacturer recommends periodic liver function tests during therapy, particularly in patients with preexisting liver dysfunction.

References

  1. Strom J, Jun H "Kinetics of hydrolysis of methenamine." Pharm Bull 23 (1975): 651
  2. Gleckman R, Alvarez S, Joubert D, Matthews S "Drug therapy reviews: methenamine mandelate and methenamine hippurate." Am J Hosp Pharm 36 (1979): 1509-12
  3. "Product Information. Mandelamine (methenamine)." Parke-Davis, Morris Plains, NJ.
  4. "Product Information. Hiprex (methenamine)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  5. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
View all 5 references
Major

Phosphates (Includes Utac) ↔ hypocalcemia

Severe Potential Hazard, High plausibility. Applies to: Hypocalcemia, Pancreatitis, Hyperkalemia

The use of phosphates is in general contraindicated in conditions where high potassium, high phosphate, or low calcium may be encountered such as hypoparathyroidism, osteomalacia, acute pancreatitis, or chronic renal disease.

References

  1. "Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals, Tampa, FL.
  2. "Product Information. Fleet Enema (sodium biphosphate-sodium phosphate)." Fleet, Lynchburg, VA.
Major

Sodium salts (Includes Utac) ↔ sodium/water imbalance

Severe Potential Hazard, High plausibility. Applies to: Congestive Heart Failure, Hypokalemia, Fluid Retention, Hypernatremia

Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.

References

  1. "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmaceutical Company, San Antonio, TX.
  3. "Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals, San Clemente, CA.

Utac (methenamine / sodium acid phosphate) drug interactions

There are 251 drug interactions with Utac (methenamine / sodium acid phosphate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide